Atea Pharmaceuticals (NASDAQ:AVIR) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Atea Pharmaceuticals (NASDAQ:AVIR) announced its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05), Zacks reports.

Atea Pharmaceuticals Trading Down 0.3 %

NASDAQ:AVIR traded down $0.01 during trading hours on Thursday, reaching $3.00. The company had a trading volume of 307,043 shares, compared to its average volume of 280,587. The firm’s 50 day moving average price is $3.17 and its 200-day moving average price is $3.35. The firm has a market cap of $253.39 million, a price-to-earnings ratio of -1.45 and a beta of 0.18. Atea Pharmaceuticals has a 52 week low of $2.75 and a 52 week high of $4.18.

Insider Transactions at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 359,606 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now directly owns 451,897 shares in the company, valued at $1,287,906.45. The trade was a 44.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 17.80% of the company’s stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.